Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2002 35
2003 51
2004 83
2005 87
2006 100
2007 129
2008 147
2009 163
2010 166
2011 231
2012 269
2013 341
2014 387
2015 435
2016 403
2017 492
2018 553
2019 638
2020 764
2021 955
2022 1109
2023 981
2024 1165
2025 1210
2026 979
2027 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,542 results

Results by year

Filters applied: . Clear all
Page 1
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial.
Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D, Zhuo M, Chen H, Huang W, Zhu Z, Zhang M, Song Y, Li Q, Ma Z, Wang Q, Qu Y, Yu R, Yu H, Zhao J, Shi A; Trial Management Group. Yu J, et al. Among authors: zhang m. Lancet Respir Med. 2024 Oct;12(10):799-809. doi: 10.1016/S2213-2600(24)00189-9. Epub 2024 Aug 12. Lancet Respir Med. 2024. PMID: 39146944 Clinical Trial.
Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.
Lai K, Sun D, Dai R, Samoro R, Park HS, Åstrand A, Cohen D, Jison M, Shih VH, Werkström V, Yao Y, Zhang Y, Zheng W, Zhong N; MIRACLE Study Investigators; Principle investigators; Albert A Jr, Jianping B, Bi C, Lijun C, Mei C, Min C, Ping C, Zhimin C, Chih-Feng C, Sook CY, Xiuhua F, Xiwen G, Wei G, Wei H, Zhihai H, Wei HX, Kewu H, Mao H, Grace Dawn IM, Inbeom J, Luning J, Mingyan J, Shanping J, Meiling J, Jian K, Woo KJ, Sang-Ha K, Jiulong K, Ping-Hung K, Jie L, Manxiang L, Minjing L, Ruoran L, Wen L, Xianhua L, Yanming L, Yong LS, Chuanhe L, Chuntao L, Jing L, Xiaoxia L, Huiyu L, Zhuang L, Shengxi M, Liangping M, Hoon MK, Lin M, Choon-Sik P, Sim PH, Hye-Kyung P, Jung-Won P, Diahn-Warng P, Ronnie S, Guochao S, Debin S, Dejun S, Chun-Hua W, Guangfa W, Limin W, Xuefen W, Yan W, Liping W, Haihong W, Yi X, Zuke X, Canmao X, Jin-Fu X, Xingxiang X, Xiyuan X, Jianping Y, Hongzhong Y, Joo YH, Wencheng Y, Jin Z, Longju Z, Min Z, Wei Z, Jianping Z, Ziwen Z, Xiaoli Z, Yingqun Z; Other investigators; AstraZenenca; ClinChoice. Lai K, et al. Among authors: min z. Respir Med. 2024 Apr 1:107611. doi: 10.1016/j.rmed.2024.107611. Online ahead of print. Respir Med. 2024. PMID: 38570145 Free article.
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study.
Xu JF, Zheng HZ, Lu HW, Wang LW, Wu B, Lv XD, Luo H, Feng J, Li YY, Liu L, Jia JG, Mo WQ, Gu HY, Jiang JB, Wang DX, Wang B, Li L, Yuan Z, Li W, Xie M, Jie ZJ, Fan XY, Li D, Tian X, Zhang M, Guan WJ, Fan H, Song YL, He J, Chu DJ, Du CL, Zhang JQ, Cao C, Qu JM, Chalmers JD; BE-China Registry Investigators. Xu JF, et al. Among authors: zhang m. Lancet Respir Med. 2025 Feb;13(2):166-176. doi: 10.1016/S2213-2600(24)00364-3. Epub 2025 Jan 10. Lancet Respir Med. 2025. PMID: 39805296 Free article.
A geroprotective probiotic and its functional metabolite counteract inflammaging to extend healthspan.
Lu X, Ping J, Han Z, Zhang S, Liu L, Xiong M, Fan Y, Li J, Sun X, Yang P, Zheng K, Wang ZK, Ping J, Xiong Y, Zuo Y, Zhang M, Li J, Wu Q, Wang Q, Gao DD, Jiang B, Sun S, Ma S, Wang S, Qu J, Yang YG, Zhang F, Liu GH, Zhang W. Lu X, et al. Among authors: zhang m. Nat Aging. 2026 Sep;6(9):1946-1966. doi: 10.1038/s43587-026-01181-4. Epub 2026 Aug 25. Nat Aging. 2026. PMID: 42642521
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
Yu J, Xiong A, Wang Q, Chen J, Niu H, Zhou C, Tian P, Zhuang W, Li J, Wang J, Lu J, Gu K, Shi J, Guo J, Di Y, Lv D, Sun D, Cao L, Yang Z, Wu J, Miao L, Pan Y, Li C, Wu X, Yin J, Wang X, Sun M, He M, Cang S, Fang H, Chen P, Zhang M, Yang X, Zhao H, Feng J, Ma X, Hu S, Lu J, Zhao X, Zhuang Z, Sun Y, Sun X, Yu B, Zhu C, Chen J, Xu J, Wang K, Zhou C. Yu J, et al. Among authors: zhang m. Signal Transduct Target Ther. 2026 Aug 13;11(1):324. doi: 10.1038/s41392-026-02904-0. Signal Transduct Target Ther. 2026. PMID: 42586967 Free PMC article. Clinical Trial.
Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial.
Writing Committee for the PEARL Investigators; Yang X, He X, Xu Y, Pan D, Li K, Chen Y, Zhu Y, Pan Y, Yi T, Zhang M, Peng H, Huang W, Li D, Feng J, Chen J, Lu W, Liao B, Xie Y, Liao B, Yang L, Tang L, Han B, Liu Y, Lin P, Chen J, Liang Y, Li D, Weng G, Huang H, Li H, Li C, Peng Z, Li H, He B, Xue R, Bao M, Sun H, Hou H, Zhou H, Xiao Y, Li J, Zhang W, Chen X, Yan W, Pi Y, Deng Z, Wang J, Xie D, Liu M, Li H, Peng Q, Fang W, Lin X, Chen Z, Li H, Lin Y, Lin Q, Xiao S, Miao Z, Wang D, Nguyen TN, Nogueira RG, Liu Y, Tang Y; PEARL investigators. Writing Committee for the PEARL Investigators, et al. Among authors: zhang m. JAMA. 2025 Oct 13;334(19):1728-39. doi: 10.1001/jama.2025.16876. Online ahead of print. JAMA. 2025. PMID: 42262770 Free PMC article.
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.
Gibson V, Dzialo J, Messier T, Bzura A, Poile C, Rogel J, Hahne JC, Habibovic A, Stead S, Saaman A, Blyth KG, Szlosarek PW, Lord S, Thistlethwaite F, Zhang M, Nakas A, Wells-Jordan P, Kutywayo K, Butnor KJ, Heintz NH, Naumov GN, Dungey M, Colomina JH, Aktas B, Dulloo S, Spicer J, Fennell DA, Cunniff B. Gibson V, et al. Among authors: zhang m. Nat Commun. 2026 Jul 14;17(1):5929. doi: 10.1038/s41467-026-75153-y. Nat Commun. 2026. PMID: 42448681 Free PMC article. Clinical Trial.
PICH deficiency attenuates the progression of lung adenocarcinoma and disrupts the DNA damage response.
Miao L, Weina L, Jiafei L, Gaoying C, Yinghui Y, Yinfang W, Fei L, Chao Z, Haoyu T, Qingyu W, Kua Z, Shenwei G, Yanping W, Chen Z, Min Z, Fangyi Y, Rui J, Zhihua C, Xinwei G, Songmin Y, Wen L. Miao L, et al. Among authors: min z. Clin Transl Med. 2025 May;15(5):e70349. doi: 10.1002/ctm2.70349. Clin Transl Med. 2025. PMID: 40442039 Free PMC article. No abstract available.
What's next for metabolomics?
Reisdorph N, Broeckling CD, Brüschweiler R, Clish CB, Copié V, Ebbels TM, Edison AS, Fernández FM, Günther UL, Mathé EA, Phelan VV, Powers R, Raftery D, Schock TB, Vuckovic D, Wishart DS, Zhang M, Want E. Reisdorph N, et al. Among authors: zhang m. Curr Opin Biotechnol. 2026 Sep 17;102:103582. doi: 10.1016/j.copbio.2026.103582. Online ahead of print. Curr Opin Biotechnol. 2026. PMID: 42753414 Review.
10,542 results
You have reached the last available page of results. Please see the User Guide for more information.